With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News

Young Woman Lost for Words Months After Stillbirth

Coexisting headache, blurred vision and nausea offer diagnostic clues

Kennedy's New Autism Research Program Aims to Speed Diagnoses

— ARPA-H launches SPECTRA autism research initiative

Gabapentin Use Rose as Restrictions Fell, Study Shows

Descheduling gabapentin in Michigan was tied to an immediate increase in dispensing

The Paradigm Shift in Neuro-Oncology: Precision Decision-Making for IDH1/2 Mutated Gliomas

All that Glitters Isn't Gold: An Exploration of Parkinson's Disease Mimics

FDA Clears Blood Test to Detect Alzheimer's in Primary and Specialty Care

Assay measures phosphorylated tau 217, an indicator of amyloid pathology

Todays Updates

Diagnosis of Mass Confined to the Kidney: Is It RCC or TCC?

Ureteroscopy and histopathology should be considered as routine preoperative assessments

BRAF Inhibition in Pediatric Ameloblastoma of the Jaw

Targeted therapy in 3 boys allowed for conservative surgery to restore jaw to predisease state

Todays Updates

Diagnosis of Mass Confined to the Kidney: Is It RCC or TCC?

Ureteroscopy and histopathology should be considered as routine preoperative assessments

BRAF Inhibition in Pediatric Ameloblastoma of the Jaw

Targeted therapy in 3 boys allowed for conservative surgery to restore jaw to predisease state

Latest News

Coexisting headache, blurred vision and nausea offer diagnostic clues

— ARPA-H launches SPECTRA autism research initiative

Descheduling gabapentin in Michigan was tied to an immediate increase in dispensing

The Paradigm Shift in Neuro-Oncology: Precision Decision-Making for IDH1/2 Mutated Gliomas

All that Glitters Isn't Gold: An Exploration of Parkinson's Disease Mimics

Assay measures phosphorylated tau 217, an indicator of amyloid pathology

News All Time

1,081 Injuries Tied to Device; Military's COVID Shot Probe; Teen Vax Coverage Slides

Health news and commentary gathered by MedPage Today staff

Rare Brain Disorder Gets Its First FDA Drug Approval

Zilganersen targets protein buildup that drives Alexander disease

Parkinson's Risk and Carbon Monoxide: What a New Study Found

Analysis offers surprising twist to the smoking-Parkinson's puzzle

Iron, Selenium, and Dementia; Epilepsy and Education; Brain Death Conversations

News and commentary from the world of neurology and neuroscience

MS Drugs Differ Most on Relapses, Not Disability, Real-World Study Shows

In new patients, disability score changes were similar over 2 years regardless of treatment

Autism Tied to 14-Year Gap in Life Expectancy

Large U.S. study points to preventable causes of excess mortality

Trial Confirms IVIG as Useful Therapy for Inflammatory Myopathy

But thromboembolic risks could be significant

First Therapy to Target Muscle Loss in Spinal Muscular Atrophy Gets FDA Approval

Motor function may improve with adjunctive apitegromab

Alzheimer's and Liver Enzymes; Pivotal Trial Hold; Lasker Awards Honor Brain Science

News and commentary from the world of neurology and neuroscience

Aging Doctors Face a Patchwork of Cognitive Screening Policies, Study Shows

Unlike pilots, judges, and air traffic controllers, physicians rely largely on self-regulation

Trump's Surgeon General Pick Grilled Over Vaccine Stance

"I do not believe childhood vaccines cause autism," Saphier said

Case Report: What Caused This Man's Acute Paralysis?

36-year-old Asian man had epidural steroid injection for persistent back pain after unsuccessful chiropractic treatments

Man Presents With Episodic, One-Sided Facial Paralysis

Uncommon presentation of MS detailed in case report

FDA-Ordered Studies for Drugs and Devices on the Market for Years Still Aren't Done

Agency's reliance on postmarketing studies reflects a balancing act

Gene Therapy for Sanfilippo Syndrome Gets FDA Nod

Treatment is the first for MPS type IIIA

Depression Drug Trials Paused Over Side-Effect Concerns

Xenon Pharmaceuticals on Thursday said it has temporarily paused enrolling new patients in clinical studies testing ⁠its experimental drug for major and bipolar depression,...